Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TYLOX-325 vs ANTEPAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Management of moderate to severe pain requiring an opioid analgesic,Severe pain uncontrolled by non-opioid analgesics
Treatment of ascariasis (roundworm infection),Treatment of enterobiasis (pinworm infection)
1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Oxycodone: 3-5 hours (extended-release preparation); terminal half-life 4.5-5.5 hours. Clinical context: repeated dosing may lead to accumulation; half-life prolongation in elderly, renal or hepatic disease.
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Acetaminophen is primarily metabolized via conjugation (glucuronidation and sulfation) and via CYP2E1 (minor pathway forming toxic NAPQI). Oxycodone is metabolized via CYP3A4 (to noroxycodone) and CYP2D6 (to oxymorphone).
Partially metabolized in the liver; some metabolites are excreted unchanged.
Renal: acetaminophen metabolites (60-70% as glucuronide conjugate, 20-30% as sulfate conjugate, 5-10% as cysteine conjugate, 5% unchanged). Oxycodone: renal (primarily metabolites, <10% unchanged); biliary/fecal: minor (oxycodone metabolites).
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Acetaminophen: 10-25% (albumin). Oxycodone: 45% (primarily albumin).
Approximately 90% bound to plasma proteins, primarily albumin.
Acetaminophen: 0.9-1.0 L/kg; extensive distribution. Oxycodone: 2.6-3.6 L/kg; high tissue penetration including CNS.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water.
Acetaminophen: oral 85-90%. Oxycodone: oral 60-87% (variable first-pass metabolism).
Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism.
e GFR 30-60 m L/min: administer at reduced frequency (e.g., every 8-12 hours); e GFR <30 m L/min: avoid use or use with extreme caution (reduce dose by 50% and monitor); hemodialysis: not recommended due to acetaminophen accumulation.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis.
Child-Pugh A (mild): no adjustment necessary; Child-Pugh B (moderate): reduce oxycodone dose by 50% and limit acetaminophen to ≤2000 mg/day; Child-Pugh C (severe): contraindicated.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%.
Not approved for children <18 years; weight-based dosing: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg) and acetaminophen 10-15 mg/kg/dose (max 650 mg) orally every 4-6 hours as needed; total daily acetaminophen ≤75 mg/kg/day.
Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg.
Initiate at lowest dose (e.g., 1 capsule every 6 hours); titrate cautiously; avoid in patients with renal impairment or hepatic dysfunction; monitor for opioid-induced constipation, respiratory depression, and acetaminophen hepatotoxicity; consider alternative non-opioid analgesics if feasible.
Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interaction with alcohol.
None.
Respiratory depression, opioid-induced hyperalgesia, adrenal insufficiency, severe hypotension, seizures, serotonin syndrome, hepatotoxicity, risk of overdose with acetaminophen, risks of use in patients with head injury or increased intracranial pressure.
Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses.
Hypersensitivity to acetaminophen or oxycodone, significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, paralytic ileus.
Hypersensitivity to piperazine; patients with pre-existing neurological disorders such as epilepsy.
Avoid alcohol. High-fat meals may delay absorption of oxycodone but do not significantly alter overall exposure. No specific food restrictions beyond alcohol.
No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs.
Pregnancy Category C. Oxycodone crosses placenta. First trimester: risk of neural tube defects not established; avoid unless benefit outweighs risk. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome (NOWS). Third trimester: high doses near term may cause neonatal respiratory depression.
ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed.
Oxycodone is excreted in breast milk; M/P ratio approximately 3.4:1. American Academy of Pediatrics recommends cautious use; monitor infant for drowsiness, respiratory depression. Acetaminophen is compatible with breastfeeding. Overall, risk to infant is low with short-term maternal use.
Piperazine is excreted into breast milk in small amounts. The M/P ratio is not established. The American Academy of Pediatrics considers piperazine compatible with breastfeeding, but caution is advised due to potential adverse effects in nursing infants. Use only if benefits outweigh risks.
Increased clearance and volume of distribution during pregnancy may require dose adjustment. Pharmacokinetic changes: oxycodone clearance increases up to 1.6-fold in third trimester; acetaminophen clearance unchanged. Clinical monitoring of pain and adverse effects recommended; dose may need upward titration.
No specific dose adjustments recommended during pregnancy. Piperazine pharmacokinetics may be altered due to increased plasma volume and renal clearance, but standard dosing is generally used. Monitor for efficacy and adverse effects.
Tylox-325 contains oxycodone and acetaminophen. Avoid in patients with known hypersensitivity to opioids or acetaminophen. The maximum daily acetaminophen dose is 4 g; monitor for hepatotoxicity. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Coadministration with CNS depressants (e.g., benzodiazepines) increases risk of respiratory depression. Constipation is common; prescribe stool softeners prophylactically. Discontinue gradually to avoid withdrawal.
ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives.
Take exactly as prescribed; do not exceed 4 grams of acetaminophen per day from all sources.,Avoid alcohol while taking this medication.,May cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how this medication affects you.,Do not take with other medications containing acetaminophen without consulting your doctor.,Contact your doctor if you experience signs of liver damage (yellow skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing).,Store securely out of reach of others; this medication can be habit-forming and may be a target for misuse.
Take exactly as prescribed; complete full course even if symptoms improve.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Report any muscle weakness, tremors, or confusion to your doctor immediately.,For pinworm infection, all household members should be treated to prevent reinfection.,Practice strict hand hygiene and wash bed linens in hot water to reduce spread.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TYLOX-325 vs ANTEPAR, answered by our medical review team.
TYLOX-325 is a Opioid analgesic combination that works by Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.. ANTEPAR is a Anthelmintic that works by Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TYLOX-325 and ANTEPAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TYLOX-325 is: 1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.. The standard adult dose of ANTEPAR is: Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TYLOX-325 and ANTEPAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TYLOX-325 is classified as Category C. Pregnancy Category C. Oxycodone crosses placenta. First trimester: risk of neural tube defects not established; avoid unless benefit outweighs risk. Second/third trimester: chronic. ANTEPAR is classified as Category C. ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. Fir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.